Acaluni (Acalabrutinib) 100mg*60 | TLPH Laos Generic | GLT

Generic Information: Acaluni (Acalabrutinib) 100mg — Laos

Acaluni is a Lao-manufactured generic of acalabrutinib from Trans Continental Life Science & Pharmaceuticals (TLPH), a Vientiane-based manufacturer that supplies oncology generics across Southeast Asia. It is supplied as 100 mg capsules in 60-capsule packs. Acaluni is TLPH's acalabrutinib offering for mantle cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma.

TLPH uses a distinctive naming pattern across its oncology line, so buyers familiar with other TLPH products will recognise Acaluni as its acalabrutinib brand. Acalabrutinib is a second-generation BTK inhibitor originally developed as Calquence, and the 100 mg capsule is the workhorse strength used in the twice-daily regimen.

What Is Acaluni Used For?

Acaluni treats mantle cell lymphoma (MCL) in patients who have received at least one prior therapy, and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It delivers continuous BTK inhibition to control the growth of these B-cell blood cancers.

How Does Acaluni Work?

Acalabrutinib, the active ingredient in Acaluni, covalently binds to Bruton's tyrosine kinase (BTK), irreversibly inhibiting the enzyme. BTK is a key signalling node downstream of the B-cell receptor, and its blockade disrupts the survival, proliferation and migration of malignant B cells. This mechanism underlies its activity in MCL, CLL and SLL.

Indications

• Mantle cell lymphoma (MCL) after at least one prior therapy.
• Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Dosage and Administration

The recommended dose is 100 mg twice daily, taken about every 12 hours. Capsules are swallowed whole with water, with or without food, and should not be chewed or opened. Treatment continues until disease progression or unacceptable toxicity, with regular blood-count monitoring.

Side Effects

Common adverse reactions include upper respiratory tract infection, diarrhoea, headache, fatigue, nausea and musculoskeletal pain. More serious risks include bleeding, serious infections, cytopenias, second primary malignancies, atrial fibrillation and liver injury. Patients should report unusual bleeding, palpitations or signs of infection.

Storage

Store Acaluni below 30°C in the original pack, protected from moisture and out of the reach of children. Use before the expiry date.

Why Choose the GLT?

GLT verifies each Acaluni batch against TLPH's documentation and provides a transparent, traceable supply route for Lao generics. Lao-made acalabrutinib is typically priced at a small fraction of the originator's US list price — often several times lower — which makes continuous twice-daily BTK-inhibitor therapy far more sustainable. We provide purchase documentation and direct support.

How to Order Acaluni from GLT

To order Acaluni 100 mg (60 capsules), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and order type, and we confirm batch details and lead time before dispatch.

FAQ

Is Acaluni the same as Calquence? Acaluni contains the same active ingredient (acalabrutinib) at 100 mg; it is a generic manufactured in Laos by TLPH.

What is the standard dose? 100 mg twice daily, approximately every 12 hours.

How long does one pack last? A 60-capsule pack lasts 30 days at the standard twice-daily dose.